#United States #Sacramento #Lunai Bioworks #AI Discovery #BrainStorm Therapeutics

Lunai Bioworks and BrainStorm Therapeutics Unite for Neurological Research

In a groundbreaking collaboration announced on May 28, 2026, Lunai Bioworks, through its subsidiary BioSymetrics, has entered into a partnership with BrainStorm Therapeutics. This strategic alliance aims to leverage artificial intelligence (AI) and advanced human organoid models to accelerate the discovery and development of novel treatments for neurological diseases, specifically Parkinson's disease and rare genetic epilepsy.

Collaborative Foundations

The partnership is bolstered by a grant from the LouLou Foundation, marking significant funding support for their joint endeavors. By combining BioSymetrics' AI-driven methodologies with BrainStorm's unique human-derived organoid systems, the companies intend to create a robust framework for translating drug discovery into effective therapies.

The primary focus of this collaboration aligns with the recent FDA guidelines that promote innovative approaches that enhance the relevance of human testing while reducing reliance on traditional animal models. This move reflects a significant shift in how drug development may evolve, particularly for the growing healthcare burden of neurological conditions.

Innovation in Discovery

The collaboration will focus on two critical areas: rare genetic epilepsies and neurodegenerative disorders like Parkinson's disease. By integrating advanced computational analysis with organoid modeling, the companies aim to identify and prioritize therapeutic targets that could lead to more effective treatments.

Utilizing the Parkinson's Progression Markers Initiative (PPMI) dataset, the partners will analyze biomarkers associated with the progression of Parkinson's to pinpoint actionable therapeutic targets. This deep analysis serves a dual purpose: advancing precision medicine strategies and contributing to the development of CNS therapeutics designed for effective real-world application.

The Flagship Program

A highlight of the collaboration is a flagship program aimed at addressing rare genetic epilepsy. Alongside Dr. Calum MacRae from Brigham and Women's Hospital and Harvard Medical School, Lunai and BrainStorm have embarked on a mission to unveil novel therapeutic strategies that not only promise to produce mechanistic insights but also generate validated biological data crucial for development-stage assets.

The collaboration encompasses a structured framework that emphasizes rapid validation of therapeutic targets, coupling organoid, computational, and in vivo discovery strategies. This approach is designed to engage pharmaceutical partners and investors effectively, ensuring that the best opportunities are pursued and developed.

Aiming for Quality Partnerships

In the current landscape, where neurological diseases remain a significant yet underserved medical concern, the partnership between Lunai and BrainStorm aims to address these challenges directly. High rates of clinical trial failures in CNS drug development often stem from suboptimal target selection and low translational predictability. By integrating advanced human-relevant biology with AI-assisted discovery processes, the collaborators seek to enhance the confidence in their therapeutic programs, thus attracting valuable partnerships in the pharmaceutical industry.

David Weinstein, CEO of Lunai, expressed enthusiasm over the synergy created by fusing AI technology with human biologies, noting that the goal is not merely to discover but to also advance potential treatments toward clinical application and partnering with established pharmaceutical entities.

Dr. Robert Fremeau, founder of BrainStorm, echoed these sentiments, outlining the need for innovative solutions to overcome the hurdles faced in CNS drug development. Both CEOs believe that through this collaboration, they can generate high-value neurology programs that meet significant unmet needs in the healthcare sector.

Conclusion

The strategic collaboration between Lunai Bioworks and BrainStorm Therapeutics goes beyond mere discovery; it signals a potential shift in how neurological diseases may be treated in the future. With a focus on real-world applicability through AI and human-centered models, this partnership is poised to create multiple avenues for success in the development of new therapies. As they pursue regulatory milestones and partner with additional stakeholders, the implications of their research could benefit patients significantly, leading to well-informed therapeutic advancements in neurological care.